A recent JACC publication establishes a link between VWF plasma concentrations and adverse thrombotic and bleeding events in anticoagulated atrial fibrillation patients. See Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Mariano Valdés M, Vicente V, and Lip GYH. Plasma von Willebrand factor levels are an independent risk factor for adverse events Including mortality and major bleeding in anticoagulated atrial fibrillation patients. JACC 2011; doi:10.1016/j.jacc.2010.12.033.
May 14 2011
No comments here.